Barinthus Biotherapeutics plc (NASDAQ:BRNS) Short Interest Down 61.9% in December

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a large decline in short interest during the month of December. As of December 15th, there was short interest totalling 5,300 shares, a decline of 61.9% from the November 30th total of 13,900 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 53,200 shares, the days-to-cover ratio is currently 0.1 days.

Hedge Funds Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Alphabet Inc. bought a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) during the second quarter, according to its most recent filing with the SEC. The firm bought 1,513,644 shares of the company’s stock, valued at approximately $2,119,000. Barinthus Biotherapeutics comprises 0.1% of Alphabet Inc.’s holdings, making the stock its 29th biggest holding. Alphabet Inc. owned approximately 3.88% of Barinthus Biotherapeutics at the end of the most recent reporting period. 25.20% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Barinthus Biotherapeutics in a report on Tuesday, November 19th.

Barinthus Biotherapeutics Stock Performance

Barinthus Biotherapeutics stock remained flat at $1.06 during mid-day trading on Friday. 55,114 shares of the company’s stock traded hands, compared to its average volume of 29,484. Barinthus Biotherapeutics has a 52-week low of $0.80 and a 52-week high of $4.16. The business has a fifty day moving average price of $1.15 and a 200 day moving average price of $1.28. The firm has a market capitalization of $42.64 million, a PE ratio of -0.71 and a beta of -0.73.

Barinthus Biotherapeutics (NASDAQ:BRNS) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.21) EPS for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.23. The company had revenue of $14.97 million for the quarter. During the same quarter last year, the company posted ($0.37) earnings per share. Analysts expect that Barinthus Biotherapeutics will post -1.52 EPS for the current fiscal year.

About Barinthus Biotherapeutics

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.